Assessment of QoL and Outcomes with SBRT for RCC
common.study.values.description
“Assessment of QoL and Outcomes With SBRT for RCC”
Stereotactic body radiotherapy (SBRT) is an emerging radiotherapy technique that precisely delivers high doses of radiation to tumours. It has been investigated as definitive treatment for an increasing variety of primary tumours including lung, liver, prostate, and now renal cell carcinoma (RCC). The principal aims of this study are to prospectively assess quality of life (QoL) and oncologic outcomes in non-surgical patients who receive SBRT for the treatment of RCC.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-no
common.study.methods.is-healthy-yes
Radiation - SBRT
35-40 Gy delivered in 5 fractions
participant.views.study.view.additional
participant.views.study.view.scientific-title
Assessment of Quality of Life and Outcomes in Patients Treated With Stereotactic Body Radiation Therapy (SBRT) for Primary Renal Cell Carcinoma (RCC) - AQuOS-RCC
common.study.values.clinical-trial-id
NCT03108703
participant.views.study.view.id
neg93b
